Global Drug Facility adds new TB drug to its catalogue
The Global Drug Facility, which provides tuberculosis (TB) treatments to those in need in 150 countries, has listed a new drug to its product catalogue.
The addition was announced on Monday, October 28 by the TB Alliance, the non-profit organisation which developed the new treatment option.
The treatment, pretomanid, received approval by the US Food and Drug Administration in August this year, and is being commercially supplied by Mylan.
In India, generic drug maker Macleods Pharmaceuticals has already been granted a licence to market the treatment, which is part of a three-drug treatment course.
GDF’s global access price of $364 per pretomanid treatment course puts the cost of the FDA approved tuberculosis regimen at $1,040 per treatment course. In the US, the same treatment costs between $2,000-$8,000.
“The global access price of US $364 for a six-month treatment course will be available to 150 countries representing the vast majority of the global TB burden,” the TB alliance said.
Mel Spigelman, president and CEO of the TB Alliance said: “We applaud the GDF’s rapid response and view this listing as a significant milestone on the path to ensuring access for those in urgent need.”
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
